Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain
- PMID: 7535334
- PMCID: PMC2191977
- DOI: 10.1084/jem.181.4.1345
Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain
Abstract
Costimulatory molecules B7 and B7-2 interact with T cell surface receptors CD28/CTLA4 and deliver a costimulatory signal essential for T cell growth. However, the structure basis of this interaction is not known. B7 and B7-2 are members of immunoglobulin (Ig) superfamily and their extracellular portion consists of an IgV- and IgC-like domain. Here we report that a naturally occurring, alternatively spliced form of B7 reveals that exon 3-encoded IgC domain is essential for CD28/CTLA4 binding. Mutational analysis of B7 demonstrates a critical role of several amino acids around loops between strands B and C and D and E, for binding CTLA4/CD28. These amino acids are clustered to form a single binding site centered at 201Y. A comparison of the effects of mutations on the binding of CD28 and CTLA4 reveals that CD28 and CTLA4 binds to the same site on B7. These results have important implications on the role of CTLA4 and CD28 in T cell costimulation. The structure of the CD28/CTLA4-binding site also provides valuable information for immune intervention targeted at the B7/B7-2-CD28/CTLA4 interactions.
Similar articles
-
Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.J Exp Med. 1995 Sep 1;182(3):667-75. doi: 10.1084/jem.182.3.667. J Exp Med. 1995. PMID: 7544393 Free PMC article.
-
Identification of conserved amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed mutagenesis: a novel structural model of the binding site.Mol Immunol. 1998 Mar;35(4):215-25. doi: 10.1016/s0161-5890(98)00041-8. Mol Immunol. 1998. PMID: 9736337
-
Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.J Biol Chem. 1995 Sep 8;270(36):21181-7. doi: 10.1074/jbc.270.36.21181. J Biol Chem. 1995. PMID: 7545666
-
Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.Ann N Y Acad Sci. 1997 Apr 5;815:392-400. doi: 10.1111/j.1749-6632.1997.tb52090.x. Ann N Y Acad Sci. 1997. PMID: 9186685 Review.
-
CD28/CTLA-4 receptor structure, binding stoichiometry and aggregation during T-cell activation.Res Immunol. 1995 Mar-Apr;146(3):130-40. doi: 10.1016/0923-2494(96)80246-x. Res Immunol. 1995. PMID: 8525042 Review. No abstract available.
Cited by
-
Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.J Exp Med. 1995 Sep 1;182(3):667-75. doi: 10.1084/jem.182.3.667. J Exp Med. 1995. PMID: 7544393 Free PMC article.
-
B7-CTLA4 interaction enhances both production of antitumor cytotoxic T lymphocytes and resistance to tumor challenge.Proc Natl Acad Sci U S A. 1998 May 26;95(11):6284-9. doi: 10.1073/pnas.95.11.6284. Proc Natl Acad Sci U S A. 1998. PMID: 9600957 Free PMC article.
-
Identification of a costimulatory molecule rapidly induced by CD40L as CD44H.J Exp Med. 1996 Sep 1;184(3):955-61. doi: 10.1084/jem.184.3.955. J Exp Med. 1996. PMID: 9064355 Free PMC article.
-
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.J Exp Med. 2003 Jun 16;197(12):1721-30. doi: 10.1084/jem.20022089. J Exp Med. 2003. PMID: 12810690 Free PMC article.
-
Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.Molecules. 2022 May 31;27(11):3545. doi: 10.3390/molecules27113545. Molecules. 2022. PMID: 35684481 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources